BACKGROUND Interleukin‐17 (IL‐17) has been demonstrated to promote formation and
growth of hormone‐naïve prostate adenocarcinoma in mice. IL‐17's role in development of …

A key question for urologic practitioners is whether an apparently organ-confined prostate
cancer (PCa) is actually aggressive or not. The dilemma is to specifically identify among all …

Skeletal metastasis in advanced prostate cancer (PCa) patients remains a significant cause
of morbidity and mortality. Research utilizing animal models during the past decade has …

Clusterin (CLU) is cytoprotective molecular chaperone that is highly expressed in castrate-
resistant prostate cancer (CRPC). CRPC is also characterized by increased insulin-like …

Dicer is an RNase III enzyme essential for the maturation of the majority of microRNAs.
Recent studies have revealed downregulation or hemizygous loss of Dicer in many tumor …

The development of effective therapies inhibiting prostate cancer progression and
metastasis may substantially impact prostate cancer mortality and potentially reduce the …

Prostate cancer is the most common malignancy in Western Europe, of which approximately
10–20% presents with advanced or metastatic disease. Initial response with androgen …

Despite the high incidence and mortality of prostate cancer, the etiology of this disease is not
fully understood. In this study, we develop functional evidence for CBP and PTEN interaction …

BACKGROUND Autophagy has recently been found to play important roles in tumorigenesis
and leucine‐rich pentatricopeptide repeat motif‐containing protein (LRPPRC) has been …

Prostate cancer is common in men with very high mortality which is one of leading causes of
cancer-related deaths in men. The main treatment approaches for metastasized prostate …